ERBB2 and breast cancer: In particular, in the study performed by Vazquez-Martin on breast carcinoma (BC) cells, biguanide in a dose- and time-dependent manner led to a significant reduction of HER-2 expression, mainly by inhibiting the downstream effector of mTOR p70S6K1, also in an AMPK-independent way [113].